COVID-19 is reshaping the pharmaceutical supply chain
C&EN VOLUME 98, ISSUE 16 – 27/04/2020 – Rick Mullin
The coronavirus pandemic may mark a rebalancing of where drugs are made as nations recognize a security imperative
VOXEurop article – Europe’s suicidal reliance on drugs made in China
VOXEurop Article – 11/03/2020
Since two years, EFCG has been advocating for a comprehensive set of measures to reduce Europe’s dependence on China for our essential APIs. These are listed in our position paper, which has now also been mentioned in this extremely well written article on Europe’s excessive reliance on China for our essential medicines. read more.
EMA addresses the potential impact of novel coronavirus disease (COVID-19) on medicines supply in the EU
EMA Press release 10/03/2020
EMA and its partners in the European medicines regulatory network are closely monitoring the potential impact of the outbreak of the novel coronavirus disease (COVID-19) on pharmaceutical supply chains into the European Union (EU). No reports of current shortages or supply disruptions of medicines marketed in the EU due to this outbreak have been received at this point. As the public health emergency develops, shortages or disruptions cannot be excluded. read more
Pharmaceuticals in the Environment – MEPs call for action to tackle pharmaceutical pollution
EP Press release 05/03/2020
On 5th March the European Parliament’s Environment, Public Health and Food Safety Committee (ENVI) adopted a motion for resolution calling for new measures to tackle pharmaceutical pollution. read more
API manufacturers address critical medicines shortages leaving Europeans and Americans vulnerable and dependent on Asian supplies
EFCG – BPTF Press release 12/02/2020
Active Pharmaceutical Ingredients (API) manufacturers express their concerns and urge EU and US authorities for action as the Coronavirus outbreak in China further highlights the vulnerability of the pharmaceutical supply chain. read more
EU and US reach a milestone in mutual recognition of inspections of medicines manufacturers
EMA Press release 12/07/2019
With the recognition by the US Food and Drug Administration (FDA) of Slovakia, the European Union and the United States have now fully implemented the mutual recognition agreement (MRA) for inspections of manufacturing sites for certain human medicines in their respective territories.
EU Council adopts SPC waiver text voted in EP in April
The Council of the EU adopted on 14th May the SPC waiver text that was voted in the EU Parliament in April. The regulation, approved during the Agriculture and Fisheries Council meeting, still needs to be published in the Official Journal, and is expected to enter into force on July 1, 2019. The waiver affects all SPCs applied for after the regulation enters into force and the text adds that “…the exception should apply, therefore, from 1 July 2022 to a certificate that takes effect from the date of entry into force of this Regulation”.
The European Commission has adopted a Communication outlining a set of actions addressing the “Strategic Approach to Pharmaceuticals in the Environment”. The plan that the Commission presented on March 11th, identifies six action areas concerning all stages of the pharmaceutical life cycle, where improvements can be made.
EMA Booklet – From lab to patient
EMA has published a booklet describing the journey of a medicine for human use authorised through EMA, from initial research to discussions on patient access to medicines across the EU: From laboratory to patient: the journey of a centrally authorised medicine – Link.
SPC manufacturing waiver
On January 23rd, 2019, the European Parliament’s JURI Committee voted its amendments to the Commission’s proposal amending Regulation (EC 469/2009) concerning the supplementary protection certificate for medicinal products. For more information, download our briefing note. Download.